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Abstract: 
T cell signaling is critical in oral lichen planus (OLP) based on the pathogenesis of this chronic inflammatory autoimmune mucocutaneous lesion. 
Lck plays a key role in T cell signaling; ultimately this signaling affects other targets such as PI-3K. Excessive activity in PI-3K inhibits 
apoptosis and promotes uncontrolled cell growth. Molecular biomarker profiling in OLP, Chronic Interface Mucosities (CIM), Epithelial 
Dysplasia (EpD) and Oral Squamous Cell Carcinoma (SCCA) with application of the principle of biomarker voting may represent a new frontier 
in the diagnosis, assessment and the arguable debate of OLP transformation to cancer. The presence of Lck, PI-3K and Survivin, a cancer specific 
anti-apoptotic protein was assessed, using immunohistochemistry and tissue micro-array on patient samples, in OLP, SCCA, CIM and EpD. Lck 
expression was very high in 78.6 % of OLP patients compared to 3.7% in SCCA; PI-3K was high in 63% of SCCA, 100% of EpD, and 35.7% 
OLP cases. Survivin was high in 64.3% of OLP cases, 96.3% of SCCA, and 100% of EpD. CIM cases may be slightly different molecularly to 
OLP. Taken together, our data suggest that biomarker protein voting can be effectively used to isolate high-risk OLP cases.  Specifically, we 
show data with four remarkable cases demonstrating that molecular factors are predictive of histopathology. We conclude that it is safer to treat 
OLP as premalignant lesions, to adopt aggressive treatment measure in histopathologic described well and moderately differentiated SCCA, and 
to monitor progress of these diseases molecularly using individualized auto-proteomic approach.  The use of Lck inhibitors in OLP management 
needs to be investigated in the future. 
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Background: 
Oral lichen planus (OLP) is an immune mediated chronic disease [1, 
2]. It usually affects muco-cutaneous tissues although it may affect any 
part of the oral cavity [3]. It is a T cell mediated autoimmune disease 
that leads to destruction of the basal cell layer of the oral mucosa. 
Clinically, OLP may present in the mouth in reticular, erosive, 
papular, plaque-like, atrophic or bullous form [1, 3]. The use of 
molecular approaches to study the pathogenesis of OLP is increasingly 
recognized diagnostic tool, and molecular approaches should further 
elucidate and characterize OLP pathogenesis. T cell signaling plays a 
key role in the pathogenesis of OLP [4]. The src family of kinases 
includes Lck and Fyn, that signal downstream of T cell receptors [5, 6] 
these molecules play a key role in T cell differentiation, survival and 
activation [7]. Lck contributes actively to the phosphorylation of ZAP-
70 [6] and may regulate the PI-3K/Akt pathway [8, 9]. 
 
Lck is considered pro-apoptotic [10, 11] and may be involved in the 
basal cell apoptosis associated with the pathogenesis of OLP. 
However, several studies found no apoptotic evidences in the basal 
cells of OLP cases [12, 13]. Here, we hypothesize that a regulatory 
loop of T cell activation and anti-apoptotic forces are involved at the 
oral basal membrane and that may be associated, at the molecular 
level, with possible OLP transformation to squamous cell carcinomas 
(SCCA). To test this hypothesis, we studied Survivin, a critical cancer-
specific protein [14], whose expression in tissues stimulates T cells. 
Survivin belongs to inhibitor of apoptosis family and is currently a key 
molecular target in anticancer therapy. Lck ultimately leads to 
activation of the PI-3K pathway in T cells. PI-3K/Akt pathway 
regulates cell growth and proliferation. Several studies have 
demonstrated the deregulation of this pathway in several cancers [15, 
16]. PI-3K is needed for normal T cell development [17]. However, 
altered and unrestrained PI-3K signaling causes auto-immunity, an 
important determinant in OLP.   
 
SCCA of the oral tissues makes up over 90% of the oral cancers [18]. 
It may occur spontaneously particularly in the presence of risk factors 
such as tobacco, alcohol, and chronic inflammatory irritations [19]. It 
may also develop from established pre-malignant lesions. OLP may in 
some cases be a pre-malignant lesion for SCCA [20, 21], but a full 
consensus about OLP potential for cancer transformation is still 
lacking. Issues complicating the understanding of OLP transformation 
to SCCA include the uncompleted definition of diagnostic criteria for 
OLP [22], and the current limits in understanding the biology of this 
disease. Taken together, we speculate that molecular profiling may be 
a promising approach to further investigate the pathogenesis of OLP 
and SCCA.  The purpose of this study was to characterize, contrast 
and compare the molecular biomarker profiling of Lck, Survivin and 
PI-3K in OLP, chronic interface mucosities (CIM), epithelial dysplasia 
(EpD) and SCCA patients. Moreover, this study was aimed to achieve 
further molecular insights into the biology of these diseases, and 
specifically to provide additional clarification through molecular 
means on OLP – cancer transformation.  The results shown suggest a 
molecular-driven approach to the management of OLP patients. 
 
Methodology: 
Patient Sample:   
Paraffin blocks of fifty clinically diagnosed patients with OLP, EpD, 
CIM or SSCA were obtained from the University of California, Los 
Angeles (School or Dentistry, Oral Pathology archive), with IRB 
approval.  Thirteen patients (fourteen samples) had OLP, six patients 
CIM, four patients epithelial dysplasia, and twenty-seven cases were 
diagnosed with SCCA (Table 1 in supplementary material). 
 
Tissue micro-array: 
The patient samples were coded to construct tissue micro-array (TMA; 
UCLA tissue array core facility). Core size was 0.6mm. Each sample 
has three panels on the TMA. The oral pathologist (RC) examined the 
patient samples, confirmed the diagnosis, and located the ideal 
segment for use in TMA construction, which was also verified by a 
second rater.  
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Antibodies and other reagents:   
Antibodies were from Abcam, USA (www.abcam.com). Rabbit anti-
human Lck protein was used at the recommended dilution of 1:250. 
This Lck antibody does not cross react with any other Src family 
members. Rabbit anti-human Survivin protein was used at 0.5µg/ml. 
Rabbit anti-human PI-3K protein was used at the recommended 
dilution of 1:50. Biotinylated secondary goat anti-rabbit antibody was 
used with the Vectastatin avidin-biotin complex (ABC) kit (Vector 
Laboratories, USA www.vectorlabs.com). Color was developed with 
the Vector Nova Red Substrate kit. 
 
 
Figure 1: The expression levels of LCK in patients with Oral lichen planus (OLP), chronic interface mucosities (CIM), epithelial dysplasia 
(EpD), and Squamous cell carcinoma (SCCA) of the oral tissues are shown. The percentages of patient is plotted with the expression levels 
designated by signal score (Scale of 0-100, negative = ≤10, Low =11-24, high = ≥25). LCK is markedly expressed in OLP samples but low or 




Figure 2: The expression levels of survivin in patients with OLP, CIM, EpD, and SCCA of the oral tissues are shown. The percentage of patients 
is plotted with the expression levels designated by signal score (same scale as Figure 1). Survivin expression is considerable high in OLP, CIM, 
EpD and SCCA. 100% SCCA and EpD cases exhibited high survivin expression; 70% and 50% of OLP and CIM samples, respectively, showed 
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Figure 3: The expression levels of PI-3K in patients with OLP, CIM, EpD, and SCCA of the oral tissues are shown. The percentage of patient is 
plotted with the expression levels designated by signal score (same scale as Fig. 1). PI-3K expression is high in 63% of SCCA, all cases of 
epithelial dysplasia and about 35.7% of OLP cases. 
 
Immuno-histochemistry protocol:  
Immuno-histochemistry (IHC) was performed as previously described 
[4], using the specific antibodies described above. Paraffin embedded 
TMA slides were deparaffinized (60o C, 30 min), xylene washed, re-
hydrated by progressive washes in decreasing concentrations of 
ethanol, and rinsed copiously in double-distilled water. Endogenous 
peroxides were inhibited (H2O2 3%, room temp, 10 min), and antigen 
retrieval obtained with citrate buffer (0.01M, pH 6.0, microwave). 
Slides were blocked for 1 hour in blocking solution (2% normal goat 
serum [NGS] in Tween-20-supplemented Tris buffered saline [T-
TBS]). Samples were incubated at 4°C overnight with the primary 
antibodies (see above) diluted in blocking solution. Following copious 
washes in T-TBS, the anti-rabbit specific secondary antibody diluted 
in blocking solution was applied for 30 min, and washed off with 
copious T-TBS, before treatment with the ABC kit (30 min). 
Following color development, the slides were counterstained with 
hematoxylin (Vector Laboratory), rinsed, dehydrated in graded 
alcohols, mounted with Vector Permanent mounting medium, sealed, 
and stored (room temp) until viewing and analysis. 
 
Computer scanning, analysis and scoring:     
Slides were scanned at 40x magnification. The aperio imagescope 
software (Version 9.1.19.1569) was used for scoring, additional 
analysis and subsequent magnification at 8X.  Two independent 
assessors evaluated the expression (signals) of each epitope based on 
the nuclear and cytoplasmic stains. A circle of tissue on the TMA was 
scored from 0 to 100 numerical points, based on the extent of stain 
signals over the tissue. A score of 50 was interpreted as staining 
covering half of a circle of tissue, score of 75 means ¾ of the tissue 
were stained, while a score of 10 simply covers a small arc of a circle 
of tissue. Expressions of markers were ranked as low (signal scores: 
11-24), negative (signal scores: 0-10), and high (signal scores ≥ 25) 
[23].  Biopsy samples with signal scores for each marker ≥ 25 were 
identified for OLP, CIM, EpD and SCCA. The numbers of biopsy 
samples identified for each marker was transformed to percentage 
ofthe total number of biopsy samples per disease group. 
 
Results:  
High expression of Lck found in biopsies from OLP patients:   
Lck expression was rated high in 78.6% of the OLP samples, 
compared to 3.7% of SCCA, 33.3% of the CIM samples and 25.0% of 
the EpD samples (Figure 1, Table 2 in supplementary material). 
The pattern of Lck immunostaining in the OLP cases was peculiar in 
that a well distinct dense band-like appearance extended from the sub-
epithelial boundary deeper into the mucosa (Figure 4A-C). This 
pattern of sub-epithelial band prominence staining was absent in 
SCCA biopsies (Figure 4E-G) and EpD cases.  Evidence of this 
particular staining pattern in CIM was inconsistent.  
 
Survivin expression levels high in OLP despite Lck pro-apoptotic 
activity:  
Survivin expression was observed in 64.3% of biopsies from OLP 
patients (Figures 2, 5A-C, 5I) and 50.0 % of CIM cases showed high 
expression of survivin.  All EpD biopsies (100%) and 96.3% of SCCA 
biopsies presented high Survivin levels (Figures 2, 5E-G, 5J). 
Regardless of how the Lck-T cell signaling apoptotic loop operates, 
the molecular signature of Survivin was clearly prominent in OLP. 
 
PI-3K expression high in SCCA and some OLP cases:  
Results revealed that 35.7% of the OLP biopsies (Figure 3) 
demonstrated high expression of PI-3K, which was observed 
respectively in 100% and 63.0% of the EpD and SCCA biopsies.  
None of the CIM biopsies showed PI-3K convincing immunostaining, 
as they were either low (≥ 11-24 expression signal scores) or negative 
(0-10 expression signal scores) (Table 2 in supplementary material). 
OLP cases with negative, low and high expressions of PI-3K are 
shown in Figures 6A, 6B and 6C, respectively. Overall, five OLP 
biopsy samples (Table 2 in supplementary material) showed high 
levels of PI-3K (Figure 6I). SCCA cases with negative, low and high 
expressions of PI-3K are shown in Figures 6E, 6F and 6G respectively. 
 
Molecular Voting identifies four high risks OLP cases:   
Identifying high-risk patients requires assessment of disease entities 
beyond the molecular signature of a single gene, RNA or protein.  A 
panel of biomarkers must be used, whose votes (molecular signatures) 
are interpreted or counted together, and should be taken into 
consideration [23]. Using this rationale we identified those samples 
that had high expressions across the three markers, particularly the 
samples that were high in PI-3K and Survivin. Based on this approach, 
four OLP samples were identified and are regarded as high risks 
(Table 3 in supplementary material).  
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Molecular factors are suggested to be acting in advance of 
histopathology:  
A few SCCA biopsy samples with well differentiated and moderately 
differentiated histomorphology also showed high expression levels of 
Survivin and PI-3K (Table 2 in supplementary material). It is 
remarkable that all histomorphologically described EpD biopsy cases 
(Table 2 in supplementary material) showed high expression levels 
of PI-3K and Survivin, a molecular signature similar to SCCA biopsy 
cases. All (100%) of the identified high-risk OLP biopsies were high 
in PI-3K, and Survivin, and suggested an OLP molecular signature 
similar to that of SCCA, despite the fact that the histomorphology of 
these lesions were characteristic of OLP.  
 
Discussion: 
Our current data reveal high (≥ 25 expression signal score) Lck 
expression in OLP biopsies. The expression follows a sub-epithelial 
band pattern of staining. Sub-epithelial dense mononuclear infiltrates 
of T cells have been previously described in OLP. By contrast, in CIM 
biopsy samples, Lck staining appears randomly distributed. The 
percentage of biopsy samples with high expression levels of Survivin 
in EpD and SCCA is greater than that of OLP and CIM biopsy 
samples. High PI-3K expression characterizes SCCA and EpD 
biopsies. Notably, all but one OLP samples with high expression 
levels of PI-3K also express high levels of Survivin and Lck. Taken 
together, our data suggest that concurrently elevated expression of PI-
3K and Survivin in OLP lesions suggest an unfavorable molecular 
signature, one that appears typical for SCCA. By pooling the votes of 
the three markers together (biomarker voting), we identified four OLP 
biopsy samples that we concluded to be high-risk OLP lesions for 
transformation to cancer. 
 
Molecular complementation of histopathology: 
The identification of OLP biopsy samples that appears to have similar 
molecular signatures to SCCA biopsy samples may be highly 
suggestive, since these OLP lesions may represent heightened risk for 
transformation to SCCA. Histopathology remains a valued and viable 
diagnostic tool. However, in order to achieve a molecular targeted 
approach in diagnosis, prognosis and therapy, histopathology needs to 
be complemented with reliable molecular tools. Case in point, 
histopathology of breast cancer is complemented with molecular tool, 
and has become valuable in the selection of patients for appropriate 
therapy and management [24, 25]. Taken together, our results lead us 
to propose that OLP lesions that are in the process of transforming to 
SCCA present histomorphologically as OLP, but possess a certain 
molecular signature that represents the specific factors that drive 
progression to cancer. Our results demonstrate that we now have the 
capability of reliably identifying this characteristic molecular 
signature. The four EpD biopsies tested as control in this study 
revealed molecular signatures similar to SCCA. Of note, EpD is 
currently recognized as a premalignant lesion [26]. Therefore, and 
despite the limitations of a small sample size, our findings suggest that 
the above-mentioned molecular factors are preceding the phenotypic 
alterations in tissue histopathology. It follows that the histo-
morphological changes that may be caused by high expression levels 
of Survivin and PI-3K may lag behind their established molecular 
impact, and may be predictive of OLP and EpD lesions as they 
progress to cancer. 
 
 
Figure 4: LCK tissue micro-array immunohistochemistry staining for OLP (panels A, B, C, D and I) and SCCA (panels E, F, G, H and J). All 
OLP cases show high expression of LCK (≥25). Panel A represents mild high LCK expression of the right lateral tongue, B moderate-high 
expression of LCK in left buccal mucosa, C marked high expression of LCK in right buccal mucosa. Panel D refers to OLP of the right buccal 
mucosa and is used as negative control (not stained with LCK primary antibody). Panel E shows mild or no expression of LCK in SCCA 
(moderately differentiated) of the left buccal mucosa F indicates moderate LCK expression in SCCA (poorly differentiated) of right 
lateral/ventral tongue while panel G is a case of marked LCK expression in SCCA (moderately differentiated) of right retromolar pad. Panel H is 
SCCA of right retromolar pad used as negative control. Panel I is 40x magnification of the box area in panel C; panel J is 40x magnification of 
the box area in panel G. 
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Figure 5: Survivin tissue micro-array immuno-histochemistry staining for OLP (panels A, B, C, D and I) and SCCA (panels E, F, G, H and J). 
High expressions of survivin further categorized as mild, moderate and marked in OLP and SCCA. Panel A shows mild expression in right buccal 
mucosa OLP; B indicates moderate survivin expression in OLP of left buccal mucosa. Panel C suggests marked expression in OLP of gingival 
tissues. Panel D shows a negative control. Red arrow in C and D indicates site of subepithelial tissue attachment to the surface epithelium. Panel 
E represents mild survivin expression in SCCA of right ventral lateral tongue; F shows moderate expression in SCCA of left buccal mucosa, 
while G indicated marked survivin expression in SCCA of left lateral tongue. Panel H shows a negative control. Panel I is 40x magnification of 
box area in C showing prominent nuclear and cytoplasmic survivin staining in OLP; panel J is 40x magnification of box area in G showing robust 
cytoplasmic survivin expression. 
 
Molecular differentiation between OLP and other lichenoid 
reactions:   
To test the possibility that molecular tools may help characterize 
between OLP and other lichenoid reactions, we evaluated and 
compared six CIM and fourteen OLP samples. Our current preliminary 
findings with this small sample size suggest some degree of molecular 
differentiation between OLP cases and other lichenoid reactions. Case 
in point, Lck expression levels were high in 33.3% of the CIM 
samples compared to the 78.6% in OLP samples, 3.7% in SCCA and 
25% in EpD biopsies. Lck expression revealed a random pattern in 
CIM lesions, compared to an almost seamless sub-epithelial band-like 
pattern in OLP biopsies. By contrast, none of the CIM biopsy samples 
showed high PI-3K expression levels. Further molecular analysis with 
more samples will possibly assist in a clearer description of these 
related inflammatory-driven entities.  
 
Chronic inflammation, autoimmunity and cancer transformation: Is 
there any role for the Lck-PI-3K-Survivin molecular loop in OLP?   
Recent studies have shown the role of chronic inflammation in the 
generation of cancer [27]. At the molecular level, we need to 
determine at which stage inflammation ceases to be protective and 
becomes harmful, including the promotion of cancer transformation. 
Lck is a non-receptor src kinase, and studies have shown the role of 
non–receptor src kinases in cancer generation [28]. PI-3K may be 
involved in the autoimmunity described in OLP since unrestrained PI-
3K activation leads to auto-immunity and leukemia [17]. In T cells, 
Lck ultimately activates PI-3K. The deregulation of the PI-3K/Akt 
pathway is responsible for several cancers [29], which is in part the 
rationale for current anti PI-3K clinical trials in cancer management 
[30]. Acting downstream to PI-3K is Akt (protein kinase B). Akt 
functionally inhibits apoptosis and promotes cell growth. A 
modulatory switch at the PI-3K/Akt level may be hypothesized for this 
molecular loop. Therefore, it is critical to elucidate the role of Lck in 
OLP as a prototype for chronic inflammation with activated T cell 
signaling. In this context, our group has additional data-mining results 
that support the Lck-PI-3K-Akt link (Giacomelli et al.,-paper II in this 
series). Taken together, the Lck-PI-3K/Akt-Survivin molecular loop 
may play an important role in the spectrum of chronic inflammation, 
autoimmunity and cancer transformation in OLP. This loop may also 
act indirectly through activation of other pathways such as the mitogen 
activated protein kinase [31]. 
 
This model raises the next important question in OLP pathogenesis: 
Could the molecular imbalance of T cells and the local tissue 
environment in OLP itself determine whether chronic inflammation 
will be protective or lead to cancer? Interleukins, particularly 
interleukin 2 (IL-2), may be vital to the effects of chronic 
inflammation at the OLP tissue microenvironment. Our data-mining 
results supports such a possible role for IL-2 in this proposed 
molecular loop (Giacomelli et al.,-paper II in this series). This 
molecular loop involving IL-2 may further explain increase T cell 
proliferation with IL-2 [32] and subsequent continuous T cell signaling 
and activation.  
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Figure 6: PI-3K tissue micro-array immunohistochemistry staining for OLP (panels A, B, C, D and I) and SCCA (panels E, F, G, H and J). 
Expression signal scores were used to identify negative, low and high expression (same scale as Fig. 1). Panel A indicates negative expression of 
PI-3K in OLP of posterior buccal mucosa; B shows low expression of PI-3K in OLP of the left vestibule, C represents OLP of the left buccal 
mucosa. Panel D shows a negative control. Panel E indicates negative PI-3K expression for SCCA of the floor of the mouth, F shows low 
expression in SCCA of right posterolateral tongue, while G is high expression in SCCA of right retromolar pad. Panel H presents a negative 
control. Panel I is 40x magnification of box area in C with red line showing the transition from the epithelium to the subepithelial area in OLP, 
while panel J is 40x magnification of the box area in G.  
 
Conclusions: 
In conclusion, our data to date suggest that histopathological 
assessment of OLP, CIM, EpD and SCCA should be complemented 
and enhanced with molecular approaches. Taken together, our findings 
lend support to the proposition that OLP lesions may be pre-malignant, 
and that molecular assessments that involve an auto-proteomic 
approach [30] may provide novel and critical information on these 
disease entities and their natural history. This may help clarifying the 
complexities in diagnosis, further clarify the potential progression 
from OLP to SCCA, and, in the future, suggest a patient-driven, 
personalized, and molecular-based therapy. Future work based on the 
results shown here will elucidate the putative role of Lck inhibitors, 
such as A770041 [33], for the management of OLP. 
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Supplementary material  
 
Table 1: Summary of the patient demographics 
Patient  Diagnosis Age at Diagnosis Anatomical location Sex 
1 OLP 65 Left buccal mucosa F 
2 OLP 48 Right buccal Mucosa F 
3 OLP 59 Left buccal mucosa F 
4 OLP 54 Left Vestibule M 
5 *OLP 62 Right buccal mucosa M 
6 *OLP 62 Left buccal mucosa M 
7 OLP 77 Right buccal mucosa F 
8 OLP 61 Right lateral tongue M 
9 OLP 64 Gingiva area around teeth number 13 and 14 F 
10 OLP 61 Left buccal mucosa M 
11 OLP 51 Gingiva area around teeth number 6 and 14 F 
12 OLP 62 Right buccal gingival F 
13 OLP 68 Left buccal mucosa F 
14 OLP 45 Right attached gingival around teeth number 3 and 4 F 
15 CIM 58 Posterior buccal mucosa M 
16 CIM 69 Right lateral tongue F 
17 CIM 58 Left buccal mucosa F 
18 CIM 21 Gingival area around teeth number 9 and 10 M 
19 CIM 45 Right buccal mucosa M 
20 CIM 61 Right lateral tongue F 
21 EpD 57 Right postero-lateral tongue F 
22 EpD 85 Lingual area of teeth number 10 and 11 F 
23 EpD 83 Right lateral border of tongue F 
24 EpD 41 Left buccal mucosa F 
25 SCCA 60 Gingiva area around teeth number 30 to 32 F 
26 SCCA 57 Left posterior area of mandible M 
27 SCCA 91 Left maxilla F 
28 SCCA 63 Left lateral tongue M 
29 SCCA 54 Gingiva area around teeth 14 F 
30 SCCA 82 Left gingival F 
31 SCCA 57 Gingiva around teeth 18 and 19 F 
32 SCCA 81 Right posterior lateral tongue M 
33 SCCA 81 Right lateral/ventralTongue F 
34 SCCA 73 Right maxillary alveolar mass M 
35 SCCA 60 Left anterior floor of the mouth M 
36 SCCA 89 Left lateral tongue M 
37 SCCA 73 Left buccal mucosa F 
38 SCCA 51 Right floor of the mouth M 
39 SCCA 65 Right retromolar pad M 
40 SCCA 74 Left buccal mucosa M 
41 SCCA 68 Left lateral tongue F 
42 SCCA 81 Left posterior maxilla F 
43 SCCA 75 Left buccal mucosa F 
44 SCCA 80 Tongue F 
45 SCCA 42 Left lateral Tongue F 
46 SCCA 71 Right/ventral tongue M 
47 SCCA 57 Right posterior mandible M 
48 SCCA 30 Left lateral tongue M 
49 SCCA 36 Left lateral tongue M 
50 SCCA 63 Right tongue M 
51 SCCA 70 Left buccal mucosa F 
#5 and #6 are same patient but different anatomical location. OLP = Oral lichen planus; CIM = Chronic interface mucosities; EpD = Epithelial 
dysplasia and SCCA = Squamous cell carcinoma. M = Male; F = Female. 
 
Table 2: Molecular expression of markers 
Expression of Markers No Diagnosis 
PI-3K LCK Survivin 
1 OLP N H H 
2 OLP N L L 
3 OLP H H L 
4 OLP L H H 
5 *OLP L H H 
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6 *OLP N H H 
7 OLP L H H 
8 OLP H H H 
9 OLP H H H 
10 OLP H H H 
11 OLP H H H 
12 OLP N L L 
13 OLP N L L 
14 OLP L H L 
15 CIM N N L 
16 CIM N L H 
17 CIM N H L 
18 CIM N H L 
19 CIM L N H 
20 CIM L L H 
21 EpD H N H 
22 EpD H N H 
23 EpD H H H 
24 EpD H L H 
25 SCCA N L H 
26 SCCA L N H 
27 SCCA N N H 
28 SCCA H N H 
29 SCCA H N H 
30 SCCA H N H 
31 SCCA H N H 
32 SCCA H N H 
33 SCCA H H H 
34 SCCA H N H 
35 SCCA N N L 
36 SCCA H N H 
37 SCCA H N H 
38 SCCA H N H 
39 SCCA H L H 
40 SCCA H N H 
41 SCCA H N H 
42 SCCA N N H 
43 SCCA N N H 
44 SCCA N N H 
45 SCCA N N H 
46 SCCA H N H 
47 SCCA H N H 
48 SCCA N N H 
49 SCCA L N H 
50 SCCA H N H 
51 SCCA H N H 
*5 and 6 are same patient but different anatomical location. OLP = Oral lichen planus; CIM = Chronic interface mucosities; EpD = Epithelial 
dysplasia and SCCA = Squamous cell carcinoma; High (H) =≥ 25 signal score, Low (L) = 11-24 signal score, N (N) =< 10 signal score 
 
Table 3: Data on OLP patients considered as high risks 










1 OLP 61 Right lateral tongue M H H H Much lymphocytes, 
keratin layer with obvious 
focal thickening 
Obvious white lacey 
lesion 
2 OLP 64 Gingiva area around 
teeth number 13 and 
14 
F H H H Much lymphocytes, thick 
orthokeratin layer 
- 
3 OLP 61 Left buccal mucosa M H H H Thickened parakeratin 
layer. Much lymphocytes 
Asymptomatic white 
straie lesion 
4 OLP 51 Gingiva area around 
teeth number 6 and 
14 
F H H H Much lymphocytes 3-4 months history of 
gingival inflammation 
High (H) => 25 score; Low (L) = 11-24 signal score; Negative (N) =< 10 signal score 
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